Adline Chem Lab Ltd Stock Price Today (NSE: ADLINE)
Fundamental Score
Adline Chem Lab Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Adline Chem Lab Ltd share price today is ₹14.38, up +0.00% on NSE/BSE as of 7 August 2026. Adline Chem Lab Ltd (ADLINE) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹8.41 (Cr). The 52-week high for ADLINE share price is ₹18.10 and the 52-week low is ₹7.60.
Adline Chem Lab Ltd Share Price Chart — NSE/BSE Historical Performance
Adline Chem Lab Ltd share price chart: 4.96% return over the past month. 52-week high ₹18.10, 52-week low ₹7.60.
Adline Chem Lab Ltd — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹14.38 | ₹14.38 | ₹14.38 | ₹14.38 | 0.00 (Cr) | |
| ₹14.38 | ₹14.38 | ₹14.38 | ₹14.38 | 0.00 (Cr) | |
| ₹14.38 | ₹14.38 | ₹14.38 | ₹14.38 | 0.00 (Cr) | |
| ₹14.38 | ₹14.38 | ₹14.38 | ₹14.38 | 0.00 (Cr) | |
| ₹14.38 | ₹14.38 | ₹14.38 | ₹14.38 | 0.00 (Cr) | |
| ₹14.38 | ₹14.38 | ₹14.38 | ₹14.38 | 0.00 (Cr) | |
| ₹14.38 | ₹14.38 | ₹14.38 | ₹14.38 | 0.00 (Cr) | |
| ₹14.38 | ₹14.38 | ₹14.38 | ₹14.38 | 0.00 (Cr) | |
| ₹14.38 | ₹14.38 | ₹14.38 | ₹14.38 | 0.00 (Cr) | |
| ₹14.38 | ₹14.38 | ₹14.38 | ₹14.38 | 0.00 (Cr) |
Adline Chem Lab Ltd — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹14.38 | ₹14.38 | ₹14.38 | ₹14.38 | +0.00% | |
| ₹13.70 | ₹14.38 | ₹13.70 | ₹14.38 | +4.96% | |
| ₹13.70 | ₹13.70 | ₹13.70 | ₹13.70 | +0.00% | |
| ₹11.28 | ₹13.70 | ₹11.28 | ₹13.70 | +21.45% | |
| ₹12.50 | ₹12.50 | ₹10.75 | ₹11.28 | -9.76% | |
| ₹13.32 | ₹13.32 | ₹12.05 | ₹12.50 | -6.16% | |
| ₹13.56 | ₹15.48 | ₹12.34 | ₹14.02 | +3.39% | |
| ₹8.78 | ₹12.31 | ₹8.78 | ₹12.31 | +40.21% | |
| ₹8.40 | ₹9.21 | ₹7.60 | ₹8.78 | +4.52% | |
| ₹14.15 | ₹14.89 | ₹8.40 | ₹8.40 | -40.64% | |
| ₹17.95 | ₹17.95 | ₹14.65 | ₹14.89 | -17.05% | |
| ₹17.95 | ₹17.95 | ₹17.95 | ₹17.95 | +0.00% |
AI Research Briefing
Powered by Gemini · 2026-08-01
Adline Chem Lab is a revenue-less micro-cap shell with negative book value and persistent cash burn, offering zero fundamental margin of safety.
WHAT'S HAPPENING NOW (last 2-4 weeks)
No major commercial catalysts, contract wins, or product launches found in live searches. The company reported a net loss of ₹0.09 Cr for Q4 FY26 with zero revenue from operations, following a full-year FY26 net loss of ₹0.28 Cr. Corporate action was restricted to governance shuffling, appointing Vrushank Balkrushna Patel as Chairman and Managing Director and Gokani Gopika Mukesh as Compliance Officer.
CORE STORY (THE REAL GAME)
This is a shell-like micro-cap vehicle with zero top-line generation, masquerading as a pharmaceutical entity. The market treats it as a penny-stock operator playground rather than an actual operating pharma company.
- Zero reported revenue for Q4 FY26 and full year FY26
- Full-year FY26 net loss expanded to ₹0.28 Cr
- Management restructuring with new CMD appointment in April 2026
- Reverse merger or asset injection into the shell
- Operator-driven low-float momentum bursts
- Promoter equity dilution or capital infusion
- Extreme liquidity and micro-cap execution risk with market cap of ₹8.41 Cr
- Negative ROCE of -933.33% and negative book value of -₹3.02
- Zero top-line revenue generation in recent quarters
FII: 0.0% (Δ 0.0%), DII: 0.0% (Δ 0.0%), Promoter: 25.85% (Δ 0.0%) — total institutional absence.
Indian pharma sector faces tightening regulatory oversight while micro-cap shells face acute capital scarcity.
No major news or order wins found after live search.
No; 5-Year FCF stands negative at ₹-0.34 Cr.
Operational turnaround remains non-existent without structural asset injection. Extreme downside capital risk.
Primary Thesis Risk
Complete absence of operational revenue and negative book value threatening equity value.
For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Adline Chem Lab Ltd Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Adline Chem Lab Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of ADLINE across key market metrics for learning purposes.
Positive Indicators
1 factors identified
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
6 factors identified
Suboptimal ROCE (-933.33%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Profit Decline Concern (-142.86%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes.
Weak Interest Coverage (-0.78x)
Observation: Limited ability to service debt obligations from earnings.
Analysis: Low interest coverage raises concerns about financial stability.
Negative Free Cash Flow (₹-0.34 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
Low Promoter Commitment (25.85%)
Observation: Reduced promoter stake may indicate limited confidence.
Analysis: Low promoter holding may raise questions about management commitment.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Adline Chem Lab Ltd vs Pharmaceuticals & Biotechnology Peers
Peer Comparison - Pharmaceuticals & Biotechnology
Compare Adline Chem Lab Ltd with 1 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Adline Chem Lab LtdAdline Chem Lab...Selected✓ ADLINE • 524604 | 5.3/100 | ₹14.38₹14 | ₹8.41₹8.41 | — — | — — | -933.33%Poor -933.33% Poor | — — | 12.24%Good 12.24% Good | — — | 0.00% |
Ind SwiftInd Swift... INDSWFTLTD • 524652 | 45.8/100 | ₹15.76₹16 | ₹92.30₹92.30 | 11.80Average 11.8 Average | — — | 11.86%Average 11.86% Average | — — | 18.19%Excellent 18.19% Excellent | 9.35%Good 9.35% Good | 0.00% |
Adline Chem Lab Ltd Quarterly Performance
Latest quarterly metrics for ADLINE — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
N/A
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
-142.86%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
N/A
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
12.24%
Compounded annual net profit growth over 5 years
Adline Chem Lab Ltd Technical Indicators
SMA 50, SMA 200, RSI and volume signals for ADLINE — calculated from daily price history
Momentum is strong — price may be stretched. Watch for pullbacks.
Technical indicators are for educational purposes only. Not investment advice.
Adline Chem Lab Ltd Financial Statements
Annual income statement, balance sheet and cash flow for Adline Chem Lab Ltd (ADLINE) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for Adline Chem Lab Ltd
About ADLINE (Adline Chem Lab Ltd)
Adline Chem Lab Ltd is a pioneering force in the pharmaceutical and biotechnology sectors, dedicated to advancing global health through innovative research, development, and manufa...cturing. With a steadfast commitment to scientific excellence, ADLINE strives to address unmet medical needs and improve patient outcomes worldwide. The company's core values of integrity, quality, and innovation underpin every aspect of its operations, from cutting-edge research laboratories to state-of-the-art manufacturing facilities. ADLINE is driven by a team of highly skilled scientists, engineers, and healthcare professionals who are passionate about pushing the boundaries of medical science and delivering life-changing therapies to those who need them most. ADLINE's diverse portfolio of pharmaceutical and biotechnology products encompasses a wide range of therapeutic areas, reflecting its dedication to comprehensive healthcare solutions. The company specializes in developing and commercializing novel treatments for infectious diseases, gastrointestinal disorders, and musculoskeletal conditions, addressing critical healthcare challenges faced by patients across the globe. Furthermore, ADLINE provides essential medicines for pediatric care, women's health, and respiratory ailments, ensuring that patients of all ages have access to high-quality healthcare solutions. These products are available in various formulations, including tablets, capsules, liquids, and injectables, to cater to diverse patient needs and preferences. Beyond its commitment to human health, ADLINE also extends its expertise to veterinary medicine, providing animal healthcare solutions that promote the well-being of pets and livestock. The company develops and manufactures a range of veterinary pharmaceuticals and nutritional supplements, addressing the specific health needs of animals and supporting the agricultural industry. Additionally, ADLINE is dedicated to advancing medical knowledge through educational initiatives, providing healthcare professionals with the latest scientific insights and clinical guidelines. This holistic approach to healthcare, encompassing both human and animal well-being, positions ADLINE as a trusted partner in promoting global health and improving the quality of life for all.
Company Details
Key Leadership
Latest News
ADLINE Share Price: Frequently Asked Questions
What is the current share price of Adline Chem Lab Ltd?
Adline Chem Lab Ltd (ADLINE) trades at ₹14.38 on NSE and BSE. Market cap ₹8.41 (Cr). Educational data only.
What is the P/E ratio of Adline Chem Lab Ltd?
Adline Chem Lab Ltd has a P/E of N/Ax vs industry average 34.89x.
What is the Bull Run score for Adline Chem Lab Ltd?
Adline Chem Lab Ltd has a Bull Run score of 5.3/100 based on 25+ financial parameters.
Does Adline Chem Lab Ltd pay dividends?
Adline Chem Lab Ltd has a dividend yield of 0.00%. Past dividends don't guarantee future payments.
What is the ROE of Adline Chem Lab Ltd?
Adline Chem Lab Ltd has ROE of N/A. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Adline Chem Lab Ltd?
Adline Chem Lab Ltd has debt-to-equity of N/A.
Is Adline Chem Lab Ltd a good investment?
Bull Run gives Adline Chem Lab Ltd a score of 5.3/100. This is not investment advice — consult a SEBI-registered advisor.